Drugs / Banxiaxiexin decoction
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05586464 | Nov 2022 → Sep 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06340724 | Feb → Nov 2024 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07035613 | Feb 2024 → Jun 2025 | inflammatory bowel disease | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Banxia Xiexin Decoction | “The goal of this exploratory, single-arm intervention study is to evaluate whether Banxia Xiexin Decoction (BXD) can prevent colitis by modulating gut microbiota composition...” NCT07035613 ↗ |
| Known as | BXD | “The goal of this exploratory, single-arm intervention study is to evaluate whether Banxia Xiexin Decoction (BXD) can prevent colitis by modulating gut microbiota composition...” NCT07035613 ↗ |
| Route | Oral | “liquid-medicine orally three times daily” NCT06340724 ↗ |